Boston, MA, United States of America

Pascal André Stein

This inventor holds 4 USPTO granted patents and 4 EPO patents. Top assignee: Merck Patent Gmbh. Active years: 2011-2015.


% Patents Active = 100.0

 

Average Co-Inventor Count = 3.4

ph-index = 3

Forward Citations = 27(Granted Patents)


Company Filing History:


Years Active: 2011-2015

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Pascal André Stein

Introduction

Pascal André Stein is a prominent inventor based in Boston, MA (US). He has made significant contributions to the field of biotechnology, particularly in cancer treatment. With a total of 4 patents to his name, Stein's work focuses on improving therapeutic methods through innovative polypeptide modifications.

Latest Patents

Stein's latest patents include groundbreaking methods for treating cancer using interleukin-12p40 variants that exhibit improved stability. These modified interleukin-12 (IL-12) p40 polypeptides have been engineered to eliminate the protease site between positions Lys260 and Arg261, resulting in enhanced stability compared to the wild-type mature human IL-12p40 polypeptides. Another notable patent involves anti-CD19 antibodies with reduced immunogenicity. The modified anti-CD19 B4 antibodies feature alterations in the variable regions, which help to minimize T-cell responses, thereby improving their therapeutic potential.

Career Highlights

Stein is currently associated with Merck Patent GmbH, where he continues to advance his research and development efforts. His work has been instrumental in creating innovative solutions that address critical health challenges.

Collaborations

Stein collaborates with esteemed colleagues such as Suzanne P McKenzie and Kin-Ming Lo, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Pascal André Stein's contributions to biotechnology and cancer treatment exemplify the impact of innovative thinking in the medical field. His patents reflect a commitment to improving patient outcomes through advanced therapeutic methods.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…